WIN 65579Alternative Names: SR 265579
Latest Information Update: 08 Aug 2007
At a glance
- Originator Sanofi-Synthelabo
- Developer Chinoin; Sanofi Winthrop; Sanofi-Synthelabo
- Class Bronchodilators
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma; Cardiovascular disorders